Subsequent Events (Details) - Subsequent Event	Feb. 13, 2017 USD ($) country shares	Feb. 02, 2017 USD ($)
Endoceutics License Agreement | Intrarosa Product
Subsequent Event [Line Items]
Supplier period	2 years
License Agreement | Palatin License Agreement
Subsequent Event [Line Items]
Research payment		$ 60,000,000
Aggregate research reimbursement expense (up to)		$ 25,000,000.0
Expiration period, following first commercial sale		10 years
License Agreement | Palatin License Agreement | Regulatory milestone
Subsequent Event [Line Items]
Future contingent payments		$ 80,000,000.0
License Agreement | Palatin License Agreement | First sales milestone
Subsequent Event [Line Items]
Future contingent payments		300,000,000.0
First sales milestone		25,000,000.0
First sales milestone triggering amount		$ 250,000,000.0
License Agreement | Endoceutics License Agreement
Subsequent Event [Line Items]
Out-of-pocket expenses	$ 20,000,000
Upfront payment	$ 50,000,000
Number of unregistered shares to be issued | shares	600,000
Period after first commercial sale	10 years
Notice period	90 days
Breach curing period	90 days
Dispute resolution period	30 days
License Agreement | Endoceutics License Agreement | Valid business reason
Subsequent Event [Line Items]
Termination period	365 days
License Agreement | Endoceutics License Agreement | Safety issue
Subsequent Event [Line Items]
Termination period	60 days
License Agreement | Endoceutics License Agreement | Change of control
Subsequent Event [Line Items]
Termination period	180 days
License Agreement | Endoceutics License Agreement | Change of control | European Union
Subsequent Event [Line Items]
Number of countries competing | country	3
License Agreement | Endoceutics License Agreement | Maximum
Subsequent Event [Line Items]
Royalty percentage	20.00%
License Agreement | Endoceutics License Agreement | 180-day lock-up provision
Subsequent Event [Line Items]
Number of unregistered shares to be issued | shares	300,000
License Agreement | Endoceutics License Agreement | One-year lock-up provision
Subsequent Event [Line Items]
Number of unregistered shares to be issued | shares	300,000
License Agreement | Endoceutics License Agreement | First sales milestone | Endoceutics, Inc
Subsequent Event [Line Items]
First sales milestone	$ 15,000,000.0
First sales milestone triggering amount	150,000,000.0
License Agreement | Endoceutics License Agreement | Second sales milestone | Endoceutics, Inc
Subsequent Event [Line Items]
First sales milestone	30,000,000.0
First sales milestone triggering amount	300,000,000
License Agreement | Endoceutics License Agreement | Third sales milestone | Endoceutics, Inc
Subsequent Event [Line Items]
First sales milestone	850,000,000
First sales milestone triggering amount	500,000,000
License Agreement | Endoceutics License Agreement | Anniversary of the Closing
Subsequent Event [Line Items]
Future contingent payments	10,000,000
License Agreement | Endoceutics License Agreement | Delivery of launch quantities
Subsequent Event [Line Items]
Future contingent payments	10,000,000.0
License Agreement | Endoceutics License Agreement | Tiered royalties
Subsequent Event [Line Items]
Future contingent payments	150,000,000.0
Net sales threshold	$ 1,000,000,000